Last updated 2 days ago
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
440 patients around the world
Available in Brazil, Puerto Rico, United States
Exelixis
2Research sites
440Patients around the world
This study is for people with
Neuroendocrine tumor
Pancreatic neuroendocrine tumor
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Histologically confirmed, locally advanced/unresectable or metastatic, well-differentiated Grade 1, 2, or 3 NETs of pancreatic origin or extra-pancreatic origin.Allowed prior lines of therapy, based on the site of NET and functional status.Documented radiographic disease progression per RECIST 1.1, as assessed by the Investigator based on imaging assessments (computed tomography [CT] or magnetic resonance imaging [MRI]) within 12 months before randomization.Measurable disease according to RECIST 1.1 as determined by the Investigator.Archival tumor tissue is required, if available. If archival tumor tissue is not available, a fresh biopsy may be submitted if it can be safely and feasibly obtained. Every attempt should be made to provide tumor tissue.
- Histologically confirmed neuroendocrine carcinomas (including small cell lung cancer), medullary thyroid cancer, pheochromocytoma, paraganglioma, Merkel cell carcinoma, and mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN).Prior treatment with a vascular endothelial growth factor receptor (VEGFR) -targeting tyrosine kinase inhibitor or a mammalian target of rapamycin (mTOR) inhibitor.Systemic chemotherapy and any liver-directed or other ablative therapy within 4 weeks before randomization.Systemic radionuclide therapy within 6 weeks before randomization.Radiation therapy for bone metastases within 2 weeks, any other radiation therapy, except as indicated above, within 4 weeks before randomization.
Sites
Hospital Moinhos de Vento - Porto Alegre
Recruiting
Pan American Center for Oncology Trials
Recruiting
StudySTELLAR-311
SponsorExelixis
Study typeInterventional
Conditions
Pancreatic neuroendocrine tumor
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06943755
